Blood cancer drugs kept on the Cancer Drugs Fund
We're delighted to announce that NHS England have confirmed that two blood cancer treatments will continue to be available to NHS patients via the Cancer Drugs Fund. The treatments were delisted from the CDF in September, but have been readmitted following negotiations between NHS England and the drugs’ manufacturers.
Ibrutinib and Brentuximab re-admitted onto the Cancer Drugs Fund
NHS England have announced that two blood cancer treatments will continue to be available to NHS patients via the Cancer Drugs Fund (CDF). The treatments were delisted from the CDF in September, but have been readmitted following negotiations between NHS England and the drugs’ manufacturers.
The drug indications readmitted onto the CDF are:
Ibrutinib for relapsed/refractory chronic lympocytic leukaemia and for relapsed/refractory mantle cell lymphoma
Brentuximab for refractory systemic anaplastic lymphoma and for relapsed or refractory CD30+ Hodgkin lymphoma
This marks a significant development for patients, with access to these medicines now secured for NHS patients. Ibrutinib and brentuximab are highly effective, and are regarded by the clinical community as the leading treatment option for these patient populations.
Diana Jupp, Director of Patient Experience at Bloodwise said:
“This is terrific news for many blood cancer patients. There was complete dismay amongst clinicians and patients when these was initially delisted in September. We welcome the negotiations undertaken by NHS England and the drug manufacturers that will allow NHS patients to continue to access them.”
“We now need to turn our attention to the remaining effective blood cancer drugs that are still unavailable for NHS patients– we hope that either through continued negotiations or through the new assessment process due to be launched next year, we can ensure blood cancer drugs have access to all effective treatments.”
Jules - Flying for everyone